Home Companies Jubilant Pharma: Fitch revises outlook to 'negative'; affirms 'BB' rating

Jubilant Pharma: Fitch revises outlook to 'negative'; affirms 'BB' rating

01:17

Fitch estimates the pharma company's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11%

from Companies https://ift.tt/mRfpokC

No comments:

Subscribe to: Post Comments ( Atom )